vs

Side-by-side financial comparison of biote Corp. (BTMD) and PETMED EXPRESS INC (PETS). Click either name above to swap in a different company.

biote Corp. is the larger business by last-quarter revenue ($46.4M vs $40.7M, roughly 1.1× PETMED EXPRESS INC). biote Corp. runs the higher net margin — 4.2% vs -26.0%, a 30.2% gap on every dollar of revenue. On growth, biote Corp. posted the faster year-over-year revenue change (-6.9% vs -23.3%). biote Corp. produced more free cash flow last quarter ($6.5M vs $-9.2M). Over the past eight quarters, biote Corp.'s revenue compounded faster (-0.4% CAGR vs -20.9%).

biote Corp is a healthcare company specializing in personalized bioidentical hormone replacement therapy solutions for adult men and women. It operates primarily in the U.S. market, offering training programs for licensed healthcare providers, along with complementary wellness supplements and diagnostic services to support patient care outcomes.

PetMed Express, Inc., also known as PetMeds, is an online pet pharmacy based in the United States. It is publicly traded and sells prescription and non-prescription pet medication.

BTMD vs PETS — Head-to-Head

Bigger by revenue
BTMD
BTMD
1.1× larger
BTMD
$46.4M
$40.7M
PETS
Growing faster (revenue YoY)
BTMD
BTMD
+16.4% gap
BTMD
-6.9%
-23.3%
PETS
Higher net margin
BTMD
BTMD
30.2% more per $
BTMD
4.2%
-26.0%
PETS
More free cash flow
BTMD
BTMD
$15.7M more FCF
BTMD
$6.5M
$-9.2M
PETS
Faster 2-yr revenue CAGR
BTMD
BTMD
Annualised
BTMD
-0.4%
-20.9%
PETS

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
BTMD
BTMD
PETS
PETS
Revenue
$46.4M
$40.7M
Net Profit
$2.0M
$-10.6M
Gross Margin
23.3%
Operating Margin
14.7%
-25.7%
Net Margin
4.2%
-26.0%
Revenue YoY
-6.9%
-23.3%
Net Profit YoY
-47.2%
-1392.6%
EPS (diluted)
$0.05
$-0.50

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BTMD
BTMD
PETS
PETS
Q4 25
$46.4M
$40.7M
Q3 25
$48.0M
$44.4M
Q2 25
$48.9M
$51.2M
Q1 25
$49.0M
$50.8M
Q4 24
$49.8M
$52.0M
Q3 24
$51.4M
$58.0M
Q2 24
$49.2M
$66.2M
Q1 24
$46.8M
$65.1M
Net Profit
BTMD
BTMD
PETS
PETS
Q4 25
$2.0M
$-10.6M
Q3 25
$8.2M
$-8.5M
Q2 25
$3.2M
$-34.2M
Q1 25
$13.7M
$-11.6M
Q4 24
$3.7M
$-707.0K
Q3 24
$10.7M
$2.3M
Q2 24
$-7.1M
$3.8M
Q1 24
$-4.2M
$-5.0M
Gross Margin
BTMD
BTMD
PETS
PETS
Q4 25
23.3%
Q3 25
28.0%
Q2 25
28.1%
Q1 25
29.9%
Q4 24
31.0%
Q3 24
32.3%
Q2 24
28.8%
Q1 24
29.3%
Operating Margin
BTMD
BTMD
PETS
PETS
Q4 25
14.7%
-25.7%
Q3 25
17.2%
-18.9%
Q2 25
22.0%
-66.7%
Q1 25
19.8%
-11.9%
Q4 24
5.6%
-0.9%
Q3 24
23.7%
1.0%
Q2 24
12.7%
6.6%
Q1 24
22.3%
-5.9%
Net Margin
BTMD
BTMD
PETS
PETS
Q4 25
4.2%
-26.0%
Q3 25
17.1%
-19.2%
Q2 25
6.5%
-66.7%
Q1 25
28.0%
-22.9%
Q4 24
7.4%
-1.4%
Q3 24
20.8%
4.0%
Q2 24
-14.4%
5.7%
Q1 24
-8.9%
-7.7%
EPS (diluted)
BTMD
BTMD
PETS
PETS
Q4 25
$0.05
$-0.50
Q3 25
$0.22
$-0.41
Q2 25
$0.10
$-1.65
Q1 25
$0.37
$-0.56
Q4 24
$0.09
$-0.03
Q3 24
$0.33
$0.11
Q2 24
$-0.21
$0.18
Q1 24
$-0.12
$-0.24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BTMD
BTMD
PETS
PETS
Cash + ST InvestmentsLiquidity on hand
$24.1M
$26.9M
Total DebtLower is stronger
$103.1M
Stockholders' EquityBook value
$-58.5M
$32.8M
Total Assets
$107.6M
$88.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BTMD
BTMD
PETS
PETS
Q4 25
$24.1M
$26.9M
Q3 25
$28.0M
$36.1M
Q2 25
$19.6M
$41.1M
Q1 25
$41.7M
$54.7M
Q4 24
$39.3M
$50.1M
Q3 24
$38.2M
$52.0M
Q2 24
$26.4M
$46.0M
Q1 24
$78.8M
$55.3M
Total Debt
BTMD
BTMD
PETS
PETS
Q4 25
$103.1M
Q3 25
$104.7M
Q2 25
$106.3M
Q1 25
$107.8M
Q4 24
$109.4M
Q3 24
$110.9M
Q2 24
$112.5M
Q1 24
$114.1M
Stockholders' Equity
BTMD
BTMD
PETS
PETS
Q4 25
$-58.5M
$32.8M
Q3 25
$-72.8M
$43.1M
Q2 25
$-85.1M
$51.5M
Q1 25
$-90.0M
$85.1M
Q4 24
$-105.9M
$96.2M
Q3 24
$-130.3M
$96.4M
Q2 24
$-143.2M
$93.5M
Q1 24
$-36.0M
$96.7M
Total Assets
BTMD
BTMD
PETS
PETS
Q4 25
$107.6M
$88.0M
Q3 25
$111.3M
$100.3M
Q2 25
$104.8M
$109.8M
Q1 25
$123.4M
$148.7M
Q4 24
$122.4M
$144.8M
Q3 24
$101.3M
$146.0M
Q2 24
$92.9M
$152.7M
Q1 24
$160.1M
$169.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BTMD
BTMD
PETS
PETS
Operating Cash FlowLast quarter
$7.6M
$-9.2M
Free Cash FlowOCF − Capex
$6.5M
$-9.2M
FCF MarginFCF / Revenue
14.0%
-22.7%
Capex IntensityCapex / Revenue
2.3%
0.1%
Cash ConversionOCF / Net Profit
3.87×
TTM Free Cash FlowTrailing 4 quarters
$30.2M
$-23.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BTMD
BTMD
PETS
PETS
Q4 25
$7.6M
$-9.2M
Q3 25
$14.1M
$-2.2M
Q2 25
$7.1M
$-12.3M
Q1 25
$6.5M
$7.0M
Q4 24
$12.4M
$-1.2M
Q3 24
$15.6M
$7.4M
Q2 24
$9.9M
$-8.5M
Q1 24
$7.4M
$7.1M
Free Cash Flow
BTMD
BTMD
PETS
PETS
Q4 25
$6.5M
$-9.2M
Q3 25
$13.6M
$-4.8M
Q2 25
$5.3M
$-13.6M
Q1 25
$4.8M
$4.6M
Q4 24
$10.7M
$-1.9M
Q3 24
$14.0M
$6.1M
Q2 24
$7.4M
$-9.2M
Q1 24
$6.7M
$5.9M
FCF Margin
BTMD
BTMD
PETS
PETS
Q4 25
14.0%
-22.7%
Q3 25
28.3%
-10.8%
Q2 25
10.8%
-26.5%
Q1 25
9.9%
9.1%
Q4 24
21.5%
-3.7%
Q3 24
27.3%
10.6%
Q2 24
15.1%
-13.9%
Q1 24
14.2%
9.0%
Capex Intensity
BTMD
BTMD
PETS
PETS
Q4 25
2.3%
0.1%
Q3 25
1.0%
5.9%
Q2 25
3.7%
2.5%
Q1 25
3.3%
4.7%
Q4 24
3.4%
1.5%
Q3 24
3.0%
2.2%
Q2 24
5.1%
1.0%
Q1 24
1.5%
1.9%
Cash Conversion
BTMD
BTMD
PETS
PETS
Q4 25
3.87×
Q3 25
1.72×
Q2 25
2.22×
Q1 25
0.47×
Q4 24
3.34×
Q3 24
1.45×
3.18×
Q2 24
-2.27×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BTMD
BTMD

Product Revenue$45.3M98%
Disposable Trocars Product Revenue$1.2M3%

PETS
PETS

Reorder$34.0M84%
New Order$5.0M12%
Membership Fees$1.6M4%

Related Comparisons